Though M&A deal value and volume both declined in biopharma in 2024 compared to the year prior, PwC analysts still believe 2025 will be an active year for the sector.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,